Free Trial

IO Biotech (IOBT) News Today

$1.27
-0.05 (-3.79%)
(As of 05/24/2024 ET)
Research Analysts Offer Predictions for IO Biotech, Inc.'s Q2 2024 Earnings (NASDAQ:IOBT)
IO Biotech, Inc. (NASDAQ:IOBT - Free Report) - Equities research analysts at HC Wainwright upped their Q2 2024 earnings per share estimates for IO Biotech in a research note issued on Wednesday, May 15th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share
HC Wainwright Boosts IO Biotech (NASDAQ:IOBT) Price Target to $12.00
HC Wainwright increased their price objective on shares of IO Biotech from $8.00 to $12.00 and gave the company a "buy" rating in a research report on Wednesday.
IO Biotech, Inc. (NASDAQ:IOBT) Major Shareholder Holdings A/S Novo Sells 658,809 Shares
IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) major shareholder Holdings A/S Novo sold 658,809 shares of the business's stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $1.22, for a total value of $803,746.98. Following the completion of the transaction, the insider now directly owns 4,429,449 shares of the company's stock, valued at $5,403,927.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.
IO Biotech, Inc. (NASDAQ:IOBT) Sees Significant Drop in Short Interest
IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the recipient of a significant drop in short interest in the month of April. As of April 30th, there was short interest totalling 39,500 shares, a drop of 36.1% from the April 15th total of 61,800 shares. Based on an average daily volume of 135,000 shares, the short-interest ratio is presently 0.3 days. Currently, 0.1% of the shares of the company are sold short.
Short Interest in IO Biotech, Inc. (NASDAQ:IOBT) Declines By 9.4%
IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the recipient of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 61,800 shares, a decline of 9.4% from the March 31st total of 68,200 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 133,900 shares, the days-to-cover ratio is currently 0.5 days.
IO Biotech presents cancer vaccine data at AACR
IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Up 50.3% in March
IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the recipient of a large growth in short interest in March. As of March 15th, there was short interest totalling 81,600 shares, a growth of 50.3% from the February 29th total of 54,300 shares. Based on an average daily trading volume, of 144,900 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.2% of the shares of the stock are sold short.
Short Interest in IO Biotech, Inc. (NASDAQ:IOBT) Rises By 10.4%
IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the target of a significant growth in short interest during the month of February. As of February 29th, there was short interest totalling 54,300 shares, a growth of 10.4% from the February 14th total of 49,200 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily volume of 148,200 shares, the days-to-cover ratio is currently 0.4 days.
Analysts Offer Predictions for IO Biotech, Inc.'s Q1 2024 Earnings (NASDAQ:IOBT)
IO Biotech, Inc. (NASDAQ:IOBT - Free Report) - Stock analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for IO Biotech in a research note issued to investors on Wednesday, March 6th. HC Wainwright analyst E. Bodnar expects that the company will earn ($0.38) per share for
IO Biotech Inc IOBT
IO Biotech (NASDAQ:IOBT) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright reissued a "buy" rating and issued a $8.00 price target on shares of IO Biotech in a research report on Wednesday.
Armistice Capital LLC Buys New Shares in IO Biotech, Inc. (NASDAQ:IOBT)
Armistice Capital LLC bought a new stake in shares of IO Biotech, Inc. (NASDAQ:IOBT - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,148,000 shares of the company's stock, valued at ap
Vivo Capital LLC Has $8.71 Million Stake in IO Biotech, Inc. (NASDAQ:IOBT)
Vivo Capital LLC grew its holdings in shares of IO Biotech, Inc. (NASDAQ:IOBT - Free Report) by 104.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,173,439 shares of the company's stock af
IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Update
IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the recipient of a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 185,500 shares, a decrease of 7.7% from the November 30th total of 200,900 shares. Currently, 0.5% of the company's shares are short sold. Based on an average daily trading volume, of 126,000 shares, the days-to-cover ratio is currently 1.5 days.
IO Biotech: A Phase 3 Company Getting No Respect
IOBT IO Biotech, Inc.
IO Biotech: Q3 Earnings Insights
IO Biotech Announces 2023 Third Quarter Results
Get IO Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter.

Gates, Bezo, and Buffett invest in AI Keystone (Ad)

In this special investigation I’m going to reveal – for the first time ever – the single most important factor in the future of AI. I’ll detail what this Keystone technology is… why it’s so critical to the future of not just AI but mankind… I’ll name the companies involved… And I’ll show you everything you need to take advantage of what could be one of the biggest financial stories of the next decade. I guarantee you’ve never seen anything like this.

Click here to read it now.

IOBT Media Mentions By Week

IOBT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IOBT
News Sentiment

0.89

0.72

Average
Medical
News Sentiment

IOBT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IOBT Articles
This Week

4

1

IOBT Articles
Average Week

Get IO Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:IOBT) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners